RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.

BACKGROUND We have previously described the essential role of the retinoid-inducible nuclear factor (RINF) during differentiation of hematopoietic cells and suggested its putative involvement in myeloid leukemia and preleukemia. Here, we have investigated whether this gene could have a deregulated expression in malignant tissues compared with their normal tissues of origin and if this potential deregulation could be associated with important clinicopathological parameters. PATIENTS AND METHODS RINF messenger RNA expression was examined in biopsies from locally advanced breast tumors, metastatic malignant melanomas, and papillary thyroid carcinomas and compared with their paired or nonpaired normal reference samples. Further, the prognostic role of RINF expression was evaluated in locally advanced breast cancer. RESULTS RINF expression was significantly higher in all tumor forms (primary breast, and thyroid cancers and metastatic melanomas) as compared with normal control tissues (P < 0.001 for each comparison). Importantly, high levels of RINF expression correlated to a poor overall survival in breast cancer (P = 0.013). This finding was confirmed in three independent public microarray datasets (P = 0.043, n = 234; P = 0.016, n = 69; P = 0.001, n = 196) and was independent of tamoxifen therapy. Notably, high levels of RINF was strongly associated with TP53 wild-type status (P = 0.002) possibly indicating that high levels of RINF could substitute for TP53 mutations as an oncogenic mechanism during the malignant development of some cases of breast cancer. CONCLUSIONS Our data indicate that (i) RINF overexpression is associated with the malignant phenotype in solid tumors and (ii) RINF overexpression represents an independent molecular marker for poor prognosis in breast tumors.

[1]  C. Purdie,et al.  High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer , 2010, International journal of cancer.

[2]  P. Lønning,et al.  MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. , 2010, European journal of cancer.

[3]  P. Lønning Molecular basis for therapy resistance , 2010, Molecular oncology.

[4]  Daniel Bottomly,et al.  Identification of β-catenin binding regions in colon cancer cells using ChIP-Seq , 2010, Nucleic acids research.

[5]  M. Rivera,et al.  A Novel Wilms Tumor 1 (WT1) Target Gene Negatively Regulates the WNT Signaling Pathway* , 2010, The Journal of Biological Chemistry.

[6]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.

[7]  N. Zeleznik-Le,et al.  Structure of the MLL CXXC domain–DNA complex and its functional role in MLL-AF9 leukemia , 2010, Nature Structural &Molecular Biology.

[8]  Min Zhang,et al.  The CXXC finger 5 protein is required for DNA damage-induced p53 activation , 2009, Science in China Series C: Life Sciences.

[9]  I. Jonassen,et al.  Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis. , 2009, Blood.

[10]  M. García-Cuéllar,et al.  Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2 , 2009, Oncogene.

[11]  O. Hermanson,et al.  CXXC5 Is a Novel BMP4-regulated Modulator of Wnt Signaling in Neural Stem Cells* , 2009, Journal of Biological Chemistry.

[12]  A. Eychène,et al.  A new MAFia in cancer , 2008, Nature Reviews Cancer.

[13]  S. Pradhan,et al.  CXXC domain of human DNMT1 is essential for enzymatic activity. , 2008, Biochemistry.

[14]  Gianluca Bontempi,et al.  Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen , 2008, BMC Genomics.

[15]  T. Yeatman,et al.  Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. , 2008, Cancer research.

[16]  M. Bycroft,et al.  Solution structure of the nonmethyl‐CpG‐binding CXXC domain of the leukaemia‐associated MLL histone methyltransferase , 2006, The EMBO journal.

[17]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Wageningen,et al.  ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells , 2005, Leukemia.

[20]  M. Cleary,et al.  Binding to Nonmethylated CpG DNA Is Essential for Target Recognition, Transactivation, and Myeloid Transformation by an MLL Oncoprotein , 2004, Molecular and Cellular Biology.

[21]  M. Katoh,et al.  Identification and characterization of human CXXC10 gene in silico. , 2004, International journal of oncology.

[22]  A. Bird,et al.  Mbd1 Is Recruited to both Methylated and Nonmethylated CpGs via Distinct DNA Binding Domains , 2004, Molecular and Cellular Biology.

[23]  K. Munger,et al.  Id Proteins - Tumor Markers or Oncogenes? , 2002, Cancer biology & therapy.

[24]  T. Aas,et al.  Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. , 2001, Cancer research.

[25]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[26]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[27]  Jiri Bartek,et al.  Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.

[28]  D. George,et al.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.

[29]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[30]  F. Alt,et al.  Transposition and amplification of oncogene-related sequences in human neuroblastomas , 1983, Cell.